isirv Antiviral Group
News
2024 | 2023 | 2022 | 2021 | 2019 | ||||||||||
Q3 2024
Neuraminidase Inhibitors
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors…read more
Occurrence and environmental fate of anti-influenza drugs in a subcatchment of the Yodo River Basin, Japan…read more
The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro…read more
Discovery of new quinoline derivatives bearing 1-aryl-1,2,3-triazole motif as influenza H1N1 virus neuraminidase inhibitors…read more
BALOXAVIR AND ENDONCULEASE INHIBTIORS
Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022–2023 influenza season in Japan…read more
High throughput profiling identified PA-L106R amino acid substitution in A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in vitro…read more
Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B…read more
Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study…read more
Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China…read more
Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States…read more
Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas…read more
NEW DRUG DISCOVERY
hnRNPAB inhibits Influenza A virus infection by disturbing polymerase activity…read more
Glycopolymer with Sulfated Fucose and 6'-Sialyllactose as a Dual-Targeted Inhibitor on Resistant Influenza A Virus Strains…read more
Design and synthesis of 7-membered lactam fused hydroxypyridinones as potent metal binding pharmacophores (MBPs) for inhibiting influenza virus PAN endonuclease…read more
Chemoenzymatic synthesis of sialyl-α2,3-lactoside-functionalized BSA conjugate inhibits influenza infection…read more
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits Interaction…read more
An N-terminal heptad repeat trimer-based peptide fusion inhibitor exhibits potent anti-H1N1 activity…read more
Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity…read more
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization…read more
PEG-SeNPs as therapeutic agents inhibiting apoptosis and inflammation of cells infected with H1N1 influenza A virus…read more
LINC01197 inhibits influenza A virus replication by serving as a PABPC1 decoy…read more
CLINICAL TRIALS AND MODELING; CASE STUDIES
Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission-Economic Evaluation Model…read more
The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system…read more
Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant…read more
REVIEWS AND COMMENTARY
Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis…read more
Harnessing PROTACs to combat H5N1 influenza: A new frontier in viral destruction…read more
Q2 2024
Neuraminidase Inhibitors
Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, May 2023-February 2024…read more
Global emergence of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses with I223V and S247N mutations: implications for antiviral resistance monitoring…read more
Impact of the H274Y Substitution on N1, N4, N5, and N8 Neuraminidase Enzymatic Properties and Expression in Reverse Genetic Influenza A Viruses…read more
Discovery and synthesis of novel benzoylhydrazone neuraminidase inhibitors…read more
Low antiviral resistance in Influenza A and B viruses isolated in Mexico from 2010 to 2023…read more
Baloxavir and Endonuclease Inhibitors
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial…read more
Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: Biological evaluation of in vitro and in vivo…read more
New Drug Discovery
Antiviral activity of adenoviral vector expressing human interferon lambda-4 against influenza virus…read more
Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract…read more
Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry…read more
Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways…read more
Spleen tyrosine kinase inhibitor R406 has both antiviral and anti-inflammatory effects on severe influenza A infection…read more
Host-directed antiviral strategy: The potential of SYK inhibitor R406 against influenza A virus infection…read more
Antiviral activity of intracellular nanobodies targeting the influenza virus RNA-polymerase core…read more
Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase…read more
Clinical Trials and Modelling, Case Studies
Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A…read more
Pharmacoeconomic study of anti-influenza virus drugs in Japan based on a network meta-analysis…read more
A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom…read more
Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons…read more
A noninferiority randomized open-label pilot study of 3- versus 7-day influenza postexposure prophylaxis with oseltamivir in hospitalized children…read more
Reviews & Commentary
Preclinical animal models to evaluate therapeutic antiviral antibodies…read more
Q1 2024
Neuraminidase Inhibitors
Inhibiting influenza virus transmission using a broadly acting neuraminidase that targets host sialic acids in the upper respiratory tract…read more
Recombinant A(H6N1)-H274Y avian influenza virus with dual drug resistance does not require permissive mutations to retain the replicative fitness in vitro and in ovo…read more
Baloxavir and Endonuclease Inhibitors
Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants…read more
Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus…read more
The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir…read more
Optimization and biological evaluation of l-DOPA derivatives as potent influenza PAN endonuclease inhibitors with multi-site binding characteristics…read more
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands…read more
New Drug Discovery & Virucides
Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus…read more
Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results…read more
Influenza A virus resistance to 4'-fluorouridine coincides with viral attenuation in vitro and in vivo…read more
Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus…read more
Clinical Trials & Case Studies
Outpacing antiviral resistance: new treatments for influenza virus infection…read more
Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey…read more
Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients…read more
Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial…read more
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season…read more
Efficacy of Pharmacotherapy for Seasonal Influenza in Young and Middle-aged Adults: A Systematic Review and Network Meta-analysis…read more
Reviews & Commentary
Commentary: Randomized, placebo-controlled trial of antiviral treatment in patients hospitalized for influenza…read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA